Illumina股价受关键阻力位打压走低 - 今日预测 - 2026年1月26日 - Economies.com
Illumina price driven lower by pivotal resistance - Forecast today - 26-01-2026 - Economies.com
生物技术与制药领域的最新动态
Illumina price driven lower by pivotal resistance - Forecast today - 26-01-2026 - Economies.com
Canaccord Genuity raises Illumina stock price target to $150 on solid results - Investing.com
Wealth Enhancement Advisory Services LLC Buys 9,997 Shares of Illumina, Inc. $ILMN - MarketBeat
iA Global Asset Management Inc. Purchases New Position in Illumina, Inc. $ILMN - MarketBeat
Is It Time To Reconsider Illumina (ILMN) After Mixed Multi Year Share Performance? - Yahoo Finance
Illumina (ILMN) Valuation Check After CMS Reimbursement Milestone In Precision Oncology - simplywall.st
Baillie Gifford & Co. Lowers Stake in Illumina, Inc. $ILMN - MarketBeat
Illumina’s billion cell atlas tries to solve artificial intelligence’s data bottleneck in biology - 2 Minute Medicine
Illumina’s billion cell atlas tries to solve artificial intelligence’s data bottleneck in biology - 2 Minute Medicine
Illumina, Inc. $ILMN Shares Sold by Teacher Retirement System of Texas - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Purchases 40,166 Shares of Illumina, Inc. $ILMN - MarketBeat
$4.5 Billion Whole Genome Sequencing Market Outlook, 2031 Featuring Profiles of Illumina, Thermo Fisher Scientific, Oxford Nanopore Technologies and Other Leading Players - Yahoo Finance Singapore
Why Illumina (ILMN) Is Up 5.9% After CMS Backs TruSight Oncology Comprehensive Reimbursement - simplywall.st
Former Illumina Executive Moves Into Quanterix’s Corner Office - Medical Product Outsourcing
Dubai Health embraces genomics to advance care and research - Illumina
Illumina (NASDAQ:ILMN) Sets New 52-Week High - Here's What Happened - MarketBeat
Illumina and Powell Gilbert in love with Lisbon - JUVE Patent
Customer Engagement Center - Illumina
Optimizing Illumina Long-Read Whole Genome Sequencing of Salivary DNA Using Oragene™ Collection Devices - the-scientist.com
Illumina Gets Reimbursement For FDA-Approved TruSight Oncology Comprehensive Test, Stock Down - Nasdaq